Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial

The Lancet Oncology 2026

View at publisher
Authors: Melissa L. Johnson, Manish R Patel, Gerald S. Falchook, Takafumi Koyama, Martin Gutierrez, Mark M. Awad, Sarina A Piha-Paul, Claire F. Friedman, Taroh Satoh, Naoko Okamoto, J. Singh, Naoto Yoshizuka
+4 more Hillarie Plessner Windish, M. Qian, Brittany P. Tran, Toshihiko Doi
DOI: 10.1016/s1470-2045(25)00733-8
Cited by: 5
References: 26

Fields of Study & Subjects

HER2/EGFR in Cancer Research Radiopharmaceutical Chemistry and Applications Peptidase Inhibition and Analysis

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
4
Pages
491–501
Publication date
31 March 2026
Language
EN